LGND - Ligand Pharmaceuticals Inc Stock Price, Fair Value and News

$122.70+1.23 (+1.01%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

LGND Price Action

Last 7 days

1.7%

Last 30 days

11.5%

Last 90 days

21.6%

Trailing 12 Months

108.9%

LGND RSI Chart

LGND Valuation

Market Cap

2.3B

Price/Earnings (Trailing)

51.24

Price/Sales (Trailing)

15.21

EV/EBITDA

23.8

Price/Free Cashflow

30.87

LGND Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

LGND Fundamentals

LGND Revenue

Revenue (TTM)

152.4M

Rev. Growth (Yr)

57.64%

Rev. Growth (Qtr)

24.76%

LGND Earnings

Earnings (TTM)

45.2M

Earnings Growth (Yr)

30.19%

Earnings Growth (Qtr)

86.18%

LGND Profitability

EBT Margin

38.59%

Return on Equity

5.38%

Return on Assets

4.74%

Free Cashflow Yield

3.24%

LGND Investor Care

Shares Dilution (1Y)

8.37%

Diluted EPS (TTM)

2.53

LGND Alerts

1 major insider sales recently.
JANUS HENDERSON GROUP PLC reported owning 5.5% of LGND [2024-11-14]
GOLDMAN SACHS GROUP INC reported owning 0.3% of LGND [2024-11-08]
Big jump in Revenue (Y/Y)
Losses in recent quarter

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	118.3M	133.5M	152.4M	0
2023	203.7M	179.9M	153.6M	131.3M
2022	231.5M	202.7M	202.3M	196.2M
2021	199.8M	237.3M	255.1M	241.5M
2020	110.0M	126.4M	143.4M	186.4M
2019	238.8M	173.7M	152.9M	120.3M
2018	251.5M	251.5M	251.5M	251.5M
2017	135.5M	206.0M	230.0M	251.5M
2016	87.0M	88.1M	92.0M	109.0M
2015	63.2M	71.0M	73.7M	71.9M
2014	53.3M	54.3M	56.3M	64.5M
2013	37.4M	41.2M	47.9M	49.0M
2012	31.8M	30.1M	30.7M	31.4M
2011	21.5M	23.1M	21.0M	30.0M
2010	0	33.8M	28.7M	23.5M
2009	0	0	0	38.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.

CEO	Mr. Todd C. Davis Ph.D.
WEBSITE	ligand.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	76

Ligand Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Ligand Pharmaceuticals Inc? What does LGND stand for in stocks?

LGND is the stock ticker symbol of Ligand Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ligand Pharmaceuticals Inc (LGND)?

As of Mon Dec 02 2024, market cap of Ligand Pharmaceuticals Inc is 2.32 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LGND stock?

You can check LGND's fair value in chart for subscribers.

Is Ligand Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether LGND is over valued or under valued. Whether Ligand Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Ligand Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LGND.

What is Ligand Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Dec 02 2024, LGND's PE ratio (Price to Earnings) is 51.24 and Price to Sales (PS) ratio is 15.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LGND PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Ligand Pharmaceuticals Inc's stock?

In the past 10 years, Ligand Pharmaceuticals Inc has provided 0.138 (multiply by 100 for percentage) rate of return.